Cardiac Myosin Activators in Heart Failure: Experimental Advances Amid Clinical Uncertainty.

While the trial met its mechanistic objectives—demonstrating improved left ventricular systolic function—the primary clinical endpoint of dyspnea relief did not reach statistical significance.

also in 111,027 other papers